Colin Zick

Colin Zick is a partner at Foley Hoag, where he co-chairs the firm’s Health Care practice and co-founded and co-chairs its Privacy & Data Security practice. Over more than three decades, he has advised pharmaceutical companies, biotechs, hospitals, and life-sciences technology vendors on healthcare regulation, compliance, cybersecurity, and data privacy.

His practice sits at the intersection of healthcare and emerging technology, which has made him an early voice on questions the industry is only beginning to confront: how artificial intelligence should be regulated, when patients should be asked to consent to its use in their care, and how to navigate a United States regulatory environment that is far more hands-off than Europe’s.

Zick appeared on Open Door Salon alongside Anne Herold Li, a shareholder at Brownstein Hyatt Farber Schreck, for a wide-ranging conversation on the legal and regulatory forces reshaping life sciences, from Supreme Court tariff rulings and the revival of the Bayh-Dole Act to the return of the Biosecure Act and the regulation of artificial intelligence.

On the Biosecure Act, Zick traced its return through the National Defense Authorization Act and what its implementation would mean for companies exposed to Chinese manufacturing. On artificial intelligence, he laid out the widening gap between a largely hands-off United States and a European Union that, by his account, pulled back from its strictest rules once it saw AI development migrating to the US and China.